CGK733 enhances multinucleated cell formation and cytotoxicity induced by taxol in Chk1-deficient HBV-positive hepatocellular carcinoma cells

Biochem Biophys Res Commun. 2012 May 25;422(1):103-8. doi: 10.1016/j.bbrc.2012.04.115. Epub 2012 Apr 30.

Abstract

Hepatocellular carcinoma (HCC) is one of the most deadly human cancers. Chronic hepatitis B virus (HBV) infection is one of the predominant risk factors associated with the development of HCC and complicates the treatment of HCC. In this study, we demonstrate that a HBV-positive HCC cell line HepG2.2.15, was more resistant to chemotherapy agents than its parental HBV-negative cell line HepG2. HBV-positive HCC cells exhibited defective Chk1 phosphorylation and increased chromosomal instability. CGK733, a small molecule inhibitor reportedly targeting the kinase activities of ATM and ATR, significantly enhanced taxol-induced cytotoxicity in HBV-positive HepG2.2.15 cells. The mechanism lies in CGK733 triggers the formation of multinucleated cells thus promotes the premature mitotic exit of taxol-induced mitotic-damaged cells through multinucleation and mitotic catastrophe in HBV-positive HepG2.2.15 cells. These results suggest that CGK733 could potentially reverse the taxol resistance in HBV-positive HCC cells and may suggest a novel strategy to treat HBV-infected HCC patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols*
  • Ataxia Telangiectasia Mutated Proteins
  • Benzeneacetamides / therapeutic use*
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / virology
  • Cell Cycle Proteins / antagonists & inhibitors
  • Checkpoint Kinase 1
  • DNA-Binding Proteins / antagonists & inhibitors
  • Drug Resistance, Neoplasm / drug effects*
  • Giant Cells / drug effects
  • Hep G2 Cells
  • Hepatitis B virus / isolation & purification
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / virology
  • Paclitaxel / therapeutic use*
  • Phosphorylation
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein Kinases / genetics
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Thiourea / analogs & derivatives*
  • Thiourea / therapeutic use
  • Tumor Suppressor Proteins / antagonists & inhibitors

Substances

  • Antineoplastic Agents, Phytogenic
  • Benzeneacetamides
  • CGK 733
  • Cell Cycle Proteins
  • DNA-Binding Proteins
  • Protein Kinase Inhibitors
  • Tumor Suppressor Proteins
  • Protein Kinases
  • ATM protein, human
  • ATR protein, human
  • Ataxia Telangiectasia Mutated Proteins
  • CHEK1 protein, human
  • Checkpoint Kinase 1
  • Protein Serine-Threonine Kinases
  • Thiourea
  • Paclitaxel